Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model

Figure 1 Body mass (A) and systolic blood pressure (B) pre-treatment (10^th week) and end of treatment (15^th week). Data are the mean ± SD, n = 5 for each group. Differences between the groups were tested with one-way ANOVA and Holm–Sidak post hoc test (P < 0.05) compared to the C group (a), HF group (c) and HFL group (e). C: Control group; HF: High-fat diet; HFL: HF diet treated with losartan; HFT: HF diet treated with telmisartan.